Early assessment of circulating tumor DNA after curative‐intent resection predicts tumor recurrence in early‐stage and locally advanced non‐small‐cell lung cancer

Circulating tumor DNA (ctDNA) has demonstrated great potential as a noninvasive biomarker to assess minimal residual disease (MRD) and profile tumor genotypes in patients with non‐small‐cell lung cancer (NSCLC). However, little is known about its dynamics during and after tumor resection, or its pot...

Descripción completa

Detalles Bibliográficos
Autores principales: Waldeck, Silvia, Mitschke, Jan, Wiesemann, Sebastian, Rassner, Michael, Andrieux, Geoffroy, Deuter, Max, Mutter, Jurik, Lüchtenborg, Anne‐Marie, Kottmann, Daniel, Titze, Laurin, Zeisel, Christoph, Jolic, Martina, Philipp, Ulrike, Lassmann, Silke, Bronsert, Peter, Greil, Christine, Rawluk, Justyna, Becker, Heiko, Isbell, Lisa, Müller, Alexandra, Doostkam, Soroush, Passlick, Bernward, Börries, Melanie, Duyster, Justus, Wehrle, Julius, Scherer, Florian, von Bubnoff, Nikolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763652/
https://www.ncbi.nlm.nih.gov/pubmed/34653314
http://dx.doi.org/10.1002/1878-0261.13116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763652/
https://www.ncbi.nlm.nih.gov/pubmed/34653314
http://dx.doi.org/10.1002/1878-0261.13116

Ejemplares similares